Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness: Justification for atherosclerosis regression treatment (JART) extension study

Ryuji Nohara, Hiroyuki Daida, Mitsumasa Hata, Kohei Kaku, Ryuzo Kawamori, Junji Kishimoto, Masahiko Kurabayashi, Izuru Masuda, Ichiro Sakuma, Tsutomu Yamazaki, Hiroyoshi Yokoi, Masayuki Yoshida

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Recently, it was reported from the Justification for Atherosclerosis Regression Treatment (JART) Study that intensive therapy with rosuvastatin significantly slowed progression of carotid intima-media thickness (IMT) compared with conventional therapy with pravastatin at 12 months. To assess the long-term efficacy of intensive therapy, the present extension study was conducted. Methods and Results: Subjects in the intensive therapy group of the JART Study were asked to participate in the extension study and to continue rosuvastatin treatment. A total of 113 subjects were enrolled into the extension study and were included in the analysis. At 24 months, the mean daily dose of rosuvastatin (± SD) was 7.9±2.9 mg. Mean change in mean IMT was -0.005 mm (range, -0.024 to 0.015 mm) at 24 months (P=0.633, compared with baseline). Rosuvastatin lowered low-density lipoprotein cholesterol (mean ± SD) by 46.4±13.8% and elevated high-density li-poprotein cholesterol (mean ± SD) by 8.9±24.0% at 24 months compared with baseline. Gray scale median was measured in 25 subjects. It increased by 16.93±33.12 (mean ± SD) % at 12 months and by 22.50±52.83% at 24 months from baseline (P=0.017, P=0.044, respectively). Conclusions: Two-year treatment with rosuvastatin inhibited progression of carotid IMT. Rosuvastatin also improved the plaque composition, and this qualitative change occurred relatively early after starting therapy.

Original languageEnglish
Pages (from-to)1526-1533
Number of pages8
JournalCirculation Journal
Volume77
Issue number6
DOIs
Publication statusPublished - May 31 2013

Fingerprint

Carotid Intima-Media Thickness
Atherosclerosis
Lipids
Therapeutics
Pravastatin
Group Psychotherapy
LDL Cholesterol
Rosuvastatin Calcium
Cholesterol

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness : Justification for atherosclerosis regression treatment (JART) extension study. / Nohara, Ryuji; Daida, Hiroyuki; Hata, Mitsumasa; Kaku, Kohei; Kawamori, Ryuzo; Kishimoto, Junji; Kurabayashi, Masahiko; Masuda, Izuru; Sakuma, Ichiro; Yamazaki, Tsutomu; Yokoi, Hiroyoshi; Yoshida, Masayuki.

In: Circulation Journal, Vol. 77, No. 6, 31.05.2013, p. 1526-1533.

Research output: Contribution to journalArticle

Nohara, Ryuji ; Daida, Hiroyuki ; Hata, Mitsumasa ; Kaku, Kohei ; Kawamori, Ryuzo ; Kishimoto, Junji ; Kurabayashi, Masahiko ; Masuda, Izuru ; Sakuma, Ichiro ; Yamazaki, Tsutomu ; Yokoi, Hiroyoshi ; Yoshida, Masayuki. / Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness : Justification for atherosclerosis regression treatment (JART) extension study. In: Circulation Journal. 2013 ; Vol. 77, No. 6. pp. 1526-1533.
@article{0fe9e032736b4ba28b44984acdc14a73,
title = "Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness: Justification for atherosclerosis regression treatment (JART) extension study",
abstract = "Background: Recently, it was reported from the Justification for Atherosclerosis Regression Treatment (JART) Study that intensive therapy with rosuvastatin significantly slowed progression of carotid intima-media thickness (IMT) compared with conventional therapy with pravastatin at 12 months. To assess the long-term efficacy of intensive therapy, the present extension study was conducted. Methods and Results: Subjects in the intensive therapy group of the JART Study were asked to participate in the extension study and to continue rosuvastatin treatment. A total of 113 subjects were enrolled into the extension study and were included in the analysis. At 24 months, the mean daily dose of rosuvastatin (± SD) was 7.9±2.9 mg. Mean change in mean IMT was -0.005 mm (range, -0.024 to 0.015 mm) at 24 months (P=0.633, compared with baseline). Rosuvastatin lowered low-density lipoprotein cholesterol (mean ± SD) by 46.4±13.8{\%} and elevated high-density li-poprotein cholesterol (mean ± SD) by 8.9±24.0{\%} at 24 months compared with baseline. Gray scale median was measured in 25 subjects. It increased by 16.93±33.12 (mean ± SD) {\%} at 12 months and by 22.50±52.83{\%} at 24 months from baseline (P=0.017, P=0.044, respectively). Conclusions: Two-year treatment with rosuvastatin inhibited progression of carotid IMT. Rosuvastatin also improved the plaque composition, and this qualitative change occurred relatively early after starting therapy.",
author = "Ryuji Nohara and Hiroyuki Daida and Mitsumasa Hata and Kohei Kaku and Ryuzo Kawamori and Junji Kishimoto and Masahiko Kurabayashi and Izuru Masuda and Ichiro Sakuma and Tsutomu Yamazaki and Hiroyoshi Yokoi and Masayuki Yoshida",
year = "2013",
month = "5",
day = "31",
doi = "10.1253/circj.CJ-12-1149",
language = "English",
volume = "77",
pages = "1526--1533",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "6",

}

TY - JOUR

T1 - Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness

T2 - Justification for atherosclerosis regression treatment (JART) extension study

AU - Nohara, Ryuji

AU - Daida, Hiroyuki

AU - Hata, Mitsumasa

AU - Kaku, Kohei

AU - Kawamori, Ryuzo

AU - Kishimoto, Junji

AU - Kurabayashi, Masahiko

AU - Masuda, Izuru

AU - Sakuma, Ichiro

AU - Yamazaki, Tsutomu

AU - Yokoi, Hiroyoshi

AU - Yoshida, Masayuki

PY - 2013/5/31

Y1 - 2013/5/31

N2 - Background: Recently, it was reported from the Justification for Atherosclerosis Regression Treatment (JART) Study that intensive therapy with rosuvastatin significantly slowed progression of carotid intima-media thickness (IMT) compared with conventional therapy with pravastatin at 12 months. To assess the long-term efficacy of intensive therapy, the present extension study was conducted. Methods and Results: Subjects in the intensive therapy group of the JART Study were asked to participate in the extension study and to continue rosuvastatin treatment. A total of 113 subjects were enrolled into the extension study and were included in the analysis. At 24 months, the mean daily dose of rosuvastatin (± SD) was 7.9±2.9 mg. Mean change in mean IMT was -0.005 mm (range, -0.024 to 0.015 mm) at 24 months (P=0.633, compared with baseline). Rosuvastatin lowered low-density lipoprotein cholesterol (mean ± SD) by 46.4±13.8% and elevated high-density li-poprotein cholesterol (mean ± SD) by 8.9±24.0% at 24 months compared with baseline. Gray scale median was measured in 25 subjects. It increased by 16.93±33.12 (mean ± SD) % at 12 months and by 22.50±52.83% at 24 months from baseline (P=0.017, P=0.044, respectively). Conclusions: Two-year treatment with rosuvastatin inhibited progression of carotid IMT. Rosuvastatin also improved the plaque composition, and this qualitative change occurred relatively early after starting therapy.

AB - Background: Recently, it was reported from the Justification for Atherosclerosis Regression Treatment (JART) Study that intensive therapy with rosuvastatin significantly slowed progression of carotid intima-media thickness (IMT) compared with conventional therapy with pravastatin at 12 months. To assess the long-term efficacy of intensive therapy, the present extension study was conducted. Methods and Results: Subjects in the intensive therapy group of the JART Study were asked to participate in the extension study and to continue rosuvastatin treatment. A total of 113 subjects were enrolled into the extension study and were included in the analysis. At 24 months, the mean daily dose of rosuvastatin (± SD) was 7.9±2.9 mg. Mean change in mean IMT was -0.005 mm (range, -0.024 to 0.015 mm) at 24 months (P=0.633, compared with baseline). Rosuvastatin lowered low-density lipoprotein cholesterol (mean ± SD) by 46.4±13.8% and elevated high-density li-poprotein cholesterol (mean ± SD) by 8.9±24.0% at 24 months compared with baseline. Gray scale median was measured in 25 subjects. It increased by 16.93±33.12 (mean ± SD) % at 12 months and by 22.50±52.83% at 24 months from baseline (P=0.017, P=0.044, respectively). Conclusions: Two-year treatment with rosuvastatin inhibited progression of carotid IMT. Rosuvastatin also improved the plaque composition, and this qualitative change occurred relatively early after starting therapy.

UR - http://www.scopus.com/inward/record.url?scp=84878216041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878216041&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-12-1149

DO - 10.1253/circj.CJ-12-1149

M3 - Article

C2 - 23486191

AN - SCOPUS:84878216041

VL - 77

SP - 1526

EP - 1533

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 6

ER -